The goal of this core facility is to provide support to various projects of this Program Project in performing tissue culture experiments in collaboration with other investigators in order to achieve the goals of the various projects as outlined in their Specific Aims. In collaboration with Dr. Arlinghaus we will improve the infection of Ph+ CML marrow cells with Ad5BCR. We will first utilize low-density marrow cells and at a later stage we will perform the same experiments with CD34+ cells. Bone marrow cells of hematologically normal individuals, chronic myelogenous leukemia (CML) at the chronic phase, and of CML patients in blastic transformation will be infected and cultured in clonogenic assays. The various clonogenic assays will be used to determine the ability of Bcr peptide to inhibit the growth of Ph+ colony-forming cells. In collaboration with Dr. Claxton we will study cells from patients who will be enrolled on protocol DM96-169. Using co-culture and clonogenic assays, we will test accessory cell anti-CML cytotoxicity following IL-2 therapy. These studies will be performed at different time points of treatment. Together with Dr. Andreeff we will study rare sub-populations of early hematopoietic progenitors in an effort to identify, isolate and grow Ph-negative hematopoietic progenitors from marrow cells of Ph+ CML patients.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA049639-11
Application #
6332472
Study Section
Project Start
2000-07-12
Project End
2001-01-31
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
11
Fiscal Year
2000
Total Cost
$79,323
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
001910777
City
Houston
State
TX
Country
United States
Zip Code
77030
Ruvolo, Peter P; Ruvolo, Vivian R; Burks, Jared K et al. (2018) Role of MSC-derived galectin 3 in the AML microenvironment. Biochim Biophys Acta Mol Cell Res 1865:959-969
Cortes, Jorge E; Gambacorti-Passerini, Carlo; Deininger, Michael W et al. (2018) Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial. J Clin Oncol 36:231-237
Sasaki, Koji; Kantarjian, Hagop; O'Brien, Susan et al. (2018) Prediction for sustained deep molecular response of BCR-ABL1 levels in patients with chronic myeloid leukemia in chronic phase. Cancer 124:1160-1168
Gambacorti-Passerini, Carlo; Cortes, Jorge E; Lipton, Jeff H et al. (2018) Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I/II study. Haematologica 103:1298-1307
Boddu, Prajwal; Shah, Abdul Rashid; Borthakur, Gautam et al. (2018) Life after ponatinib failure: outcomes of chronic and accelerated phase CML patients who discontinued ponatinib in the salvage setting. Leuk Lymphoma 59:1312-1322
Kornblau, Steven M; Ruvolo, Peter P; Wang, Rui-Yu et al. (2018) Distinct protein signatures of acute myeloid leukemia bone marrow-derived stromal cells are prognostic for patient survival. Haematologica 103:810-821
Zhang, Weiguo; Ly, Charlie; Ishizawa, Jo et al. (2018) Combinatorial targeting of XPO1 and FLT3 exerts synergistic anti-leukemia effects through induction of differentiation and apoptosis in FLT3-mutated acute myeloid leukemias: from concept to clinical trial. Haematologica 103:1642-1653
Alhuraiji, Ahmad; Kantarjian, Hagop; Boddu, Prajwal et al. (2018) Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors. Am J Hematol 93:84-90
Ishizawa, Jo; Nakamaru, Kenji; Seki, Takahiko et al. (2018) Predictive Gene Signatures Determine Tumor Sensitivity to MDM2 Inhibition. Cancer Res 78:2721-2731
Boddu, Prajwal; Benton, Christopher B; Wang, Wei et al. (2018) Erythroleukemia-historical perspectives and recent advances in diagnosis and management. Blood Rev 32:96-105

Showing the most recent 10 out of 375 publications